Skip to main content
Contact Us
Subscribe
E-Edition
37°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
25.11
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arvinas Inc
< Previous
1
2
3
4
5
6
7
Next >
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
November 14, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analyst Ratings for Arvinas
November 13, 2023
Via
Benzinga
Analyst Expectations for Arvinas's Future
October 23, 2023
Via
Benzinga
Where Arvinas Stands With Analysts
September 07, 2023
Via
Benzinga
7 Analysts Have This to Say About Arvinas
August 14, 2023
Via
Benzinga
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
October 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
August 09, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Arvinas
June 26, 2023
Via
Benzinga
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
6 Analysts Have This to Say About Arvinas
June 09, 2023
Via
Benzinga
Looking Into Arvinas's Return On Capital Employed
May 19, 2023
Via
Benzinga
Where Arvinas Stands With Analysts
May 08, 2023
Via
Benzinga
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP)
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
July 06, 2023
Collaboration expands Carrick’s clinical-stage Oncology program
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
Arvinas Announces Changes to its Board of Directors
June 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
June 08, 2023
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic
Via
Benzinga
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
June 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
May 08, 2023
Wells Fargo raised the price target for Stanley Black & Decker, Inc. (NYSE: SWK) from $85 to $90. Wells Fargo analyst Joe O'Dea maintained an Equal-Weight rating. Stanley Black & Decker shares rose 3%...
Via
Benzinga
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
